Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Merck & Co.
 More »

  • 10 Minute Charge Heterogeneity Analysis for Development and Quality...
    Carrie L. Anderson, Senior Scientist, Vaccine Analytical Development, Merck & Co. will present the wide range of applications for icIEF in biopharmaceutical development and ...
    11-12-2013
  • JobWatch: Novartis Trims California Workforce
    Merck links layoffs to AstraZeneca venture; BI says bon voyage, Ben Venue. Novartis' Vaccines & Diagnostics Division next ... the next two years, Merck & Co. has cited the need to ...
    10-9-2013
  • Young Companies in the Money: 25 Firms to Watch
    ... the corporate venture capital fund of Merck Serono has taken a minority equity stake ... existing investors include Burrill & Co. and the Kuwait Investment Authority's ...
    10-2-2013
  • Merck & Co. Axes 8,500 in R&D Restructuring
    Merck & Co. said today it will eliminate 8,500 jobs over the next two years as part of a restructuring of R&D and commercial operations that the company says will save it $2.5 ...
    10-1-2013
  • DNA Vaccines Free from Mobile DNA
    ... "mini-circles", which co-purify with plasmid DNA made by standard isolation techniques. ... In 2004, Merck scientists reported that whole plasmids could integrate into mouse genomes ...
    10-1-2013
  • HIV Researchers Seek a Potential Cure
    Frost & Sullivan predicts a compound annual growth rate ... (which encodes the major co-receptor for HIV entry into ... Merck has several compounds in Phase I and II development. ...
    10-1-2013
  • Malvern Instruments Acquires NanoSight
    As of May, NanoSight had installed more than 600 systems worldwide for customers that include pharma giants such as GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and Roche, as ...
    9-30-2013
  • Ablynx Nets Another $33.7M from Merck Serono as Partnership Expands
    and co-development arrangements. The research group will focus on discovery and development of Nanobodies spanning all Merck Serono's core R&D areas, including oncology, ...
    9-26-2013
  • Top 40 Molecular Millionaires
    ... price on April 17: $213.08 #28. Kenneth C. Frazier Chairman, President, and CEO, Merck & Co Total value of all shares: $64,254,297 18 242,561 shares of common stock 19 and ...
    9-19-2013
  • Cell-Based Assays: Getting Back to Basics
    ... our company is focusing new R&D efforts on traditional ... Millipore, a division of Merck KGaA. "This is a ... It also can be applied to study co-localization of proteins ...
    9-15-2013
  • Progress in Protein Expression Technology
    ... expression systems and process development, Merck & Co. "Unfortunately, no universal platforms are available yet for vaccines, even if one is restricted to protein antigens." ...
    9-15-2013
  • Columbia Labs Buys Molecular Profiles for $25M
    Molecular Profiles' CEO and co-founder, Nikin Patel, Ph.D ., MRPharmS, will join ... Crinone is the progesterone gel supplied by Columbia and sold mostly by Merck KGaA's Merck ...
    9-12-2013
  • AstraZeneca Licenses Merck's Cancer Candidate MK-1775
    AstraZeneca said today it will license from Merck & Co. its Phase IIa cancer drug candidate MK-1775. The $50 million-plus deal helps AstraZeneca build its pipeline in a core ...
    9-11-2013
  • Spreading Sunshine on What Biopharma Pays Physicians
    ... Besides GSK and Pfizer, Abbott Laboratories, Allergan, AstraZeneca, Cephalon (acquired by Teva Pharmaceutical Industries), Eli Lilly, Novartis, Merck & Co., two divisions of ...
    8-29-2013
  • FDA Approves Viiv Healthcare's HIV-1 Treatment Tivicay
    Four of the trials involved a total 2,557 adults with HIV across the treatment spectrum: one comparing a once-daily Tivicay-based regimen to Merck & Co.'s twice-daily Isentress ...
    8-13-2013

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll